ribavirin has been researched along with cyclosporine in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.04) | 18.2507 |
| 2000's | 11 (22.45) | 29.6817 |
| 2010's | 34 (69.39) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ahn, HJ; Akter, S; Cho, WJ; Choi, TG; Ha, J; Jang, M; Jin, Y; K R, J; Kang, I; Khadka, DB; Kim, HY; Kim, JH; Kim, M; Kim, SS; Lim, S; Oh, BC; Windisch, MP; Yang, S; Zhao, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Chevallier, P; Chossegros, P; Daoud, S; Dubernard, JM; Garnier, JL; Touraine, JL | 1 |
| Burroughs, AK; Papatheodoridis, GV; Teixeira, R | 1 |
| Eguchi, S; Hamasaki, K; Hidaka, M; Ichikawa, T; Kanematsu, T; Miyazaki, K; Soyama, A; Tajima, Y; Takatsuki, M; Tokai, H | 1 |
| Ferenci, P; Gangl, A; Peck-Radosavljevic, M; Rasoul-Rockenschaub, S; Reiberger, T; Rieger, A | 1 |
| Kato, M; Miura, H; Ryu, T; Saito, T; Yamada, H | 1 |
| Agnelli, F; Arosio, E; Colombo, M; Donato, MF; Rigamonti, C | 1 |
| Abradelo, M; Colina, F; Fernández, I; Gimeno, A; Jiménez, C; Lumbreras, C; Meneu, JC; Moreno, E; Solís-Herruzo, JA; Ulloa, E | 1 |
| Cabrera, R; Chen, C; Clark, VC; Firpi, RJ; Levy, C; Michaels, A; Morelli, GG; Nelson, DR; Soldevila-Pico, C; Suman, A | 1 |
| Di Lernia, V | 1 |
| Arvelakis, A; Assis, D; Caldwell, C; Cimsit, B; Emre, S; Kulkarni, S; Schilsky, M; Taddei, T | 1 |
| Hokari, A | 1 |
| Boillot, O; Botta-Fridlund, D; Boudjema, K; Calmus, Y; Chazouillères, O; Dharancy, S; Durand, F; Duvoux, C; Gugenheim, J; Néau-Cransac, M; Pageaux, G; Rostaing, L; Samelson, L; Samuel, D; Vanlemmens, C; Wolf, P | 1 |
| Antonini, TM; Barau, C; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Noël, C; Roche, B; Roque-Afonso, AM; Samuel, D; Taburet, AM | 1 |
| Bahra, M; Boas-Knoop, S; Eurich, D; Kiessling, A; Neuhaus, P; Neuhaus, R; Neumann, UP; Puhl, G; Trautwein, C; Wasmuth, H; Yahyazadeh, A | 1 |
| Espinales, JC; Lawitz, EJ; Membreno, FE | 1 |
| Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J | 1 |
| Guedj, J; Kern, S; Levi, M; Li, B; Naoumov, NV; Perelson, AS; Yu, J | 1 |
| Chen, K; Debing, Y; Janssen, HL; Metselaar, HJ; Neyts, J; Pan, Q; Peppelenbosch, MP; Van Der Laan, LJ; Wang, Y; Zhou, X | 1 |
| Ampuero, J; Reddy, KR; Romero-Gómez, M | 1 |
| D'Amico, E; D'Angelo, S; Gilio, M; Leccese, P; Olivieri, I; Palazzi, C | 1 |
| Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D | 1 |
| Alberti, A; Brass, C; Buti, M; Calistru, P; Chuang, WL; Davis, GL; Flisiak, R; Goeser, T; Horban, A; Kao, JH; Mazzella, G; Orsenigo, R; Pol, S; Rasenack, J; Streinu-Cercel, A; Tabak, F | 1 |
| Bernhardt, P; Duvoux, C; Firpi, RJ; Grazi, GL; Levy, G; Mulhaupt, B; Pageaux, G; Rauer, B; Renner, EL; Schirm, F; Villamil, F | 1 |
| Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Ishiyama, K; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Naeshiro, N; Ochi, H; Ohdan, H; Tashiro, H; Tsuge, M | 1 |
| Avila, C; Chuang, WL; Flisiak, R; Foster, GR; Hézode, C; Li, B; Naoumov, NV; Pawlotsky, JM; Peng, CY; Piratvisuth, T; Rasenack, J; Sarin, SK; Shah, S; Wedemeyer, H; Wong, KA; Zhang, W | 1 |
| Abdurakhmanov, D; Bao, W; Brass, C; Buggisch, P; Calistru, P; Flisiak, R; Gould, M; Griffel, LH; Heo, J; Hsu, SJ; Makara, M; Mazur, W; Mazzella, G; Merz, M; Mutimer, D; Naoumov, NV; Nault, B; Samuel, D; Stanciu, C; Thongsawat, S; Van Kính, N; Vierling, JM; Zeuzem, S | 1 |
| Bo, Q; Brass, C; Griffel, L; Orsenigo, R; Wang, J | 1 |
| Andreone, P; Berenguer, M; Calleja, JL; Cieciura, T; Donato, MF; Durlik, M; Fagiuoli, S; Forns, X; Herzer, K; Janssen, K; Jessner, W; Kalmeijer, R; Lenz, O; Mariño, Z; Ouwerkerk-Mahadevan, S; Peeters, M; Shukla, U; Sterneck, M; Verbinnen, T | 1 |
| Chang, KO; Dang, W; Felczak, K; Koopmans, MPG; Metselaar, HJ; Pan, Q; Pankiewicz, KW; Peppelenbosch, MP; Sprengers, D; Su, J; van der Laan, LJW; Wang, W; Wang, Y; Yin, Y | 1 |
| Hashimoto, S; Hayashi, K; Nakagawa, Y; Saito, K; Takahashi, K; Takamura, M; Takeuchi, S; Tanabe, Y; Tasaki, M; Terai, S; Tomita, Y; Yamagiwa, S; Yoshida, T | 1 |
| El-Hamamsy, M; El-Meteini, M; Mansy, AE; Montasser, IF; Nabet, DE | 1 |
| Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM | 1 |
| Adianti, M; Aoki-Utsubo, C; Hafid, AF; Hotta, H; Permanasari, AA; Tumewu, L; Wahyuni, TS; Widyawaruyanti, A | 1 |
| Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH | 1 |
6 review(s) available for ribavirin and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Management of recurrent hepatitis C after liver transplantation.
Topics: Adrenal Cortex Hormones; Antiviral Agents; Cyclosporine; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Secondary Prevention; Tacrolimus | 2001 |
[Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].
Topics: Antiviral Agents; Cyclosporine; Diterpenes; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fatty Alcohols; Female; Fluvastatin; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Male; Metformin; Nitro Compounds; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Silybin; Silymarin; Thiazoles | 2011 |
Cyclophilin inhibitors for hepatitis C therapy.
Topics: Antiviral Agents; Cyclophilins; Cyclosporine; Cyclosporins; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2013 |
Review article: HCV genotype 3 – the new treatment challenge.
Topics: Animals; Antiviral Agents; Cyclophilins; Cyclosporine; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Viral Nonstructural Proteins | 2014 |
An update on the management of hepatitis C virus-related arthritis.
Topics: Antirheumatic Agents; Antiviral Agents; Arthritis; Autoimmune Diseases; Cyclosporine; Disease Management; Drug Therapy, Combination; Hepacivirus; Humans; Hydroxychloroquine; Interferon-alpha; Ribavirin; Tumor Necrosis Factor-alpha | 2014 |
8 trial(s) available for ribavirin and cyclosporine
| Article | Year |
|---|---|
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Topics: Antiviral Agents; Cyclosporine; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tacrolimus | 2010 |
Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
Topics: Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Induction Chemotherapy; Interferon-alpha; Kidney; Liver Cirrhosis; Liver Transplantation; Logistic Models; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Treatment Outcome; Viral Load | 2012 |
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
Topics: Antiviral Agents; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.
Topics: Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Salvage Therapy; Treatment Outcome; Viral Load; Young Adult | 2015 |
Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tacrolimus; Treatment Outcome; Young Adult | 2015 |
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Topics: Adult; Antiviral Agents; Cyclosporine; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2015 |
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult | 2015 |
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cyclosporine; Drug Therapy, Combination; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Tacrolimus; Treatment Outcome; Valine; Viral Load | 2017 |
35 other study(ies) available for ribavirin and cyclosporine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Cyclosporine; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Replicon; Ribavirin; Viral Nonstructural Proteins | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
Topics: Animals; Antiviral Agents; Cell Line, Tumor; Cyclophilin A; Drug Synergism; Glycine; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Indoleacetic Acids; Mice, Inbred NOD; Mice, SCID; Models, Molecular; Protein Binding; Replicon; Structure-Activity Relationship; Virus Replication | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Hepatitis C virus infection in renal transplantation.
Topics: Azathioprine; Cyclosporine; Hepatitis C; Humans; Kidney Transplantation; Liver; Pancreas Transplantation; Polymerase Chain Reaction; Postoperative Complications; Ribavirin | 1995 |
Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation.
Topics: Antiviral Agents; Cohort Studies; Cyclosporine; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Tacrolimus | 2007 |
Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; CD4 Lymphocyte Count; Cyclosporine; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Tacrolimus; Treatment Outcome; Viral Load | 2008 |
[Peginterferon alfa-2b and ribavirin-induced pure red cell aplasia during treatment of chronic hepatitis C treated by cyclosporin A with good response].
Topics: Administration, Inhalation; Antiviral Agents; Cyclosporine; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin | 2008 |
Might rapid virological response be used as a stopping rule in liver transplant recipients treated with pegylated interferon plus ribavirin?
Topics: Antiviral Agents; Cohort Studies; Cyclosporine; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Kinetics; Liver; Liver Transplantation; Odds Ratio; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2008 |
Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cyclosporine; Female; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Incidence; Interferons; Liver; Liver Diseases; Liver Transplantation; Male; Middle Aged; Ribavirin; Risk Factors; Treatment Outcome | 2009 |
Treatment of psoriasis in patients with hepatitis C virus infection.
Topics: Acitretin; Antiviral Agents; Cyclosporine; Drug Eruptions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Methotrexate; Psoriasis; Ribavirin | 2011 |
Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
Topics: Antiviral Agents; Cholestasis, Intrahepatic; Cohort Studies; Cyclosporine; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Tacrolimus; Treatment Outcome | 2011 |
Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study.
Topics: Antiviral Agents; Cohort Studies; Cyclosporine; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Secondary Prevention | 2011 |
Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.
Topics: Aged; Antiviral Agents; Cyclosporine; Disease Management; Drug Therapy, Combination; Everolimus; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Tacrolimus; Viral Load | 2012 |
YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
Topics: Adipokines; Adult; Antiviral Agents; Chitinase-3-Like Protein 1; Cyclosporine; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lectins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sex Factors; Statistics, Nonparametric; Tacrolimus; Time Factors; Young Adult | 2013 |
[HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
Topics: Adult; Antiviral Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2013 |
Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus.
Topics: Antiviral Agents; Calcineurin; Calcineurin Inhibitors; Cell Line, Tumor; Cyclophilin A; Cyclophilins; Cyclosporine; Dose-Response Relationship, Drug; HEK293 Cells; Hepatitis E; Hepatitis E virus; Hepatitis, Chronic; Humans; Immunosuppressive Agents; Mycophenolic Acid; Ribavirin; RNA Interference; RNA, Viral; Time Factors; Transfection; Virus Replication | 2014 |
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Topics: Adult; Antiviral Agents; Coinfection; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2015 |
Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
Topics: Aged; Antiviral Agents; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Tacrolimus; Treatment Outcome | 2015 |
Glucose abnormalities in Asian patients with chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Asian People; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclosporine; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Interferons; Logistic Models; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Factors; Sex Factors; Treatment Outcome | 2015 |
Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication.
Topics: Antiviral Agents; Calcineurin; Calcineurin Inhibitors; Caliciviridae Infections; Cell Line; Cyclosporine; Humans; Immunosuppressive Agents; IMP Dehydrogenase; Mycophenolic Acid; Norovirus; Ribavirin; Tacrolimus; Tacrolimus Binding Protein 1A; Virus Replication | 2017 |
Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2018 |
Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Tacrolimus; Young Adult | 2019 |
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine | 2019 |
An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs.
Topics: Antiviral Agents; Artocarpus; Cell Line; Cyclosporine; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Indonesia; Oligopeptides; Plant Extracts; Plant Leaves; Ribavirin | 2021 |
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Organ Transplantation; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |